Recent News

• 02.04.2026 - Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
• 02.03.2026 - Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
• 01.14.2026 - Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045
• 11.26.2025 - Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
• 11.14.2025 - Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.17.2025 - Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
• 10.09.2025 - Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
• 10.09.2025 - Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Recent Filings

• 01.06.2026 - 8-K Current report
• 01.06.2026 - DEF 14A Other definitive proxy statements
• 12.23.2025 - PRE 14A Other preliminary proxy statements
• 12.19.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.17.2025 - EFFECT Notice of Effectiveness
• 12.12.2025 - S-3 Registration statement under Securities Act of 1933
• 12.03.2025 - D Notice of Exempt Offering of Securities
• 12.01.2025 - 8-K Current report
• 12.01.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 8-K Current report